Erika von Euw, Ph.D.

Erika von Euw, Ph.D. has over 18 years of experience in the biomedical field. In 2003, they began their career as a PhD Student at Universidad de Buenos Aires, where they generated data derived in a Phase I Clinical Trial in Immuno-Oncology for Melanoma patients. Her dissertation was titled "A Melanoma Vaccine Based on Autologous Dendritic Cells Loaded with Apo-Nec Melanoma Cells" and their thesis was "Lead Generation of Preclinical Data Package; Complete IND Submission for Several Phase I Clinical Trials: Vaccination of Melanoma Patients with Dendritic Cells Loaded with Allogeneic Apoptotic-Necrotic Melanoma Cells".

In 2008, Erika von Euw, Ph.D. joined the University of California, Los Angeles as an Assistant Professor. In this role, they evaluated project objectives, contributed scientific expertise, designed, implemented, validated and led a range of in-vitro studies. Erika also supported early stage development of potential therapeutic candidates on small molecules or mAbs side, and directed and supervised research of more than 10 Research Associates.

In 2019, Erika von Euw, Ph.D. began working at T-Cure Bioscience, Inc. as Senior Director of Translational Research. In this role, they drove program management, continuous improvement and complex cross-functional team interactions for key development of the cell therapy programs. Erika also communicated program initiatives and status to the teams, management, and other stakeholders escalating strategic decisions to senior leadership as required. In addition, they drove decision making of key stakeholders, resolved conflicts, and maintained focus of working groups. Erika also held the roles of Director of Translational Research and Associate Director of Translational Research at T-Cure Bioscience, Inc.

Currently, Erika von Euw, Ph.D. is Vice President of Discovery and Translational Research at Deverra Therapeutics. In this role, they lead target discovery and translational research of novel therapeutics for allogeneic off-the-self NK and myeloid effector cells. Erika also builds CAR-NK and CAR-MAC differentiated platforms and pipelines, allocates resources, and makes portfolio prioritization and go/no-go decisions. Additionally, they implement a non-viral gene delivery technology for the organization.

Erika von Euw, Ph.D. completed their Bachelor of Science (BS) in Biochemistry from Universidad Nacional de San Luis between 1998 and 2003. Erika then went on to pursue their Doctor of Philosophy (Ph.D.) in Immunology Oncology - Melanoma Treatment (DCs Vaccines) from the University of Buenos Aires between 2003 and 2008. Following their Ph.D., they completed Postdoctoral Studies in Cell Therapy in Oncology (TCRs) at the University of California, Los Angeles between 2008 and 2010.